Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.
The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.
Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.
The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.
It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.
“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”
“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”
Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.
“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”
[osd_subscribe categories=’anticancer-drug’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “ANTI-CANCER DRUG”‘]
Receive an email update when we add a new ANTI-CANCER DRUG article.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- Clinical Trials With Immunotherapy Drugs Are Source Of Hope And Challenges In Treating Aggressive Breast Canceron May 17, 2022 at 11:00 am
Joshalyn Mills had serious side effects from her clinical trial treatments. As a Black woman, Mills believes she wouldn’t have been offered a trial if she ...
- Cancer patients face higher risks of drug interactionson May 17, 2022 at 8:23 am
Here's a scenario so common that it applies to nearly 92% of older adults with cancer: An individual comes in for treatment and reports taking several medications that might include a drug for high ...
- DNA damage response drugs for cancer yield continued synthetic lethality learningson May 17, 2022 at 5:48 am
A PARP1-selective drug and a pipeline of ATR inhibitors demonstrate the near-term opportunities and long-term challenges for synthetic lethality in anticancer drug development.
- Small cell lung cancer subtypes respond differently to chemotherapeutics and targeted drugson May 17, 2022 at 4:53 am
Small cell lung cancer (SCLC) is a malignant disease associated with a particularly high mortality rate. According to a new multicenter study led by MedUni Vienna and conducted in collaboration with ...
- Source of hope and challenges in treating aggressive breast cancer: Connecticut clinical trials with immunotherapy drugson May 17, 2022 at 2:21 am
While there are dramatic successes with immunotherapy drugs, there are also many failures, and researchers are trying to find out why in hopes of expanding the drugs’ effectiveness.
- Genome-wide CRISPR and tumour suppressor genes could open new pathways for discovering anticancer drugson May 17, 2022 at 12:54 am
Researchers have performed CRISPR screens to uncover tumour suppressor genes vulnerabilities critical for discovering anticancer drugs ...
- Immunotherapy drug nivolumab may reduce risk of bladder cancer recurringon May 16, 2022 at 11:00 pm
Immunotherapy with nivolumab (Opdivo) after surgery for metastatic bladder cancer significantly reduces the odds for the tumor's return, a new clinical trial finds.
- Nutrition must be priority during chemotherapyon May 14, 2022 at 4:42 am
Q: I'm getting chemotherapy for breast cancer. I expected the nausea and exhaustion, but I didn't know food would start to taste metallic and just plain weird. Some days all I want are potato chips, ...
- Ask the Doctors: Nutrition must be priority during chemotherapyon May 12, 2022 at 10:00 pm
I'm getting chemotherapy for breast cancer. I expected the nausea and exhaustion, but I didn't know food would start to taste metallic and just plain weird. Some days ...
via Bing News